Appethyl's U.S. Patent, "Use of Plant Cell Membrane for the Treatment of Obesity" Issued to Greenleaf Medical AB

Company's Focus on Nutraceutical Research and Development Leads to Patented Technologies Helping Advance Health Industry

STOCKHOLM, SWEDEN--(Marketwired - May 13, 2014) - Greenleaf Medical AB announced that the company was issued patent #8,642,098 from the U.S. Patent and Trademark Office (USPTO) for their innovation in health science.

The new patent, "Use of plant cell membrane for the treatment of obesity," issued to Greenleaf Medical AB relates to the use of at least one cell membrane fraction to help retard fat digestion, suppress appetite, body weight and/or lower blood lipids. Greenleaf Medical AB's Appethyl™ uses thylakoids (a pigmented membrane found in spinach) to significantly reduce appetite and help induce weight loss.

Appethyl™ is the trade name for the clinically tested appetite suppression product from spinach that is being brought to the marketplace by Greenleaf Medical (GLM), a Swedish company that has licensed the patented technology from Lund University in Sweden. Five human studies and two animal trials conducted in 2013 have affirmed both the appetite suppression and weight loss effects found in the original pilot trials. There are now six completed clinical trials ranging from mechanism of action and acute appetite suppression to significant weight loss in double-blind, placebo-controlled clinical studies.

"In addition to the strong scientific background of Appethyl™, the U.S. Patent provides confidence for both our distributors and our customers. This is perfect timing for our upcoming U.S. launch," said Dan Edwall, chairman of the board of Greenleaf Medical AB.

Greenleaf Medical AB is currently awaiting approval on three patents including the process patent, as well as patents related to reducing absorption of sugar and one related to prebiotic effects.

The "Use of plant cell membrane for the treatment of obesity" patent is in addition to others that Greenleaf Medical AB has been issued in Korea and Australia. Greenleaf Medical AB owns full worldwide exclusivity for these patents, which have been issued to Thylabisco AB.
For more information on Appethyl™ or Greenleaf Medical AB, please visit [http://www.gl-medical.com](http://www.gl-medical.com) or contact Maria Soderberg at +46 70 869 27 06, (GMT +1) email: ms(at)gl-medical(dot)com.

About Greenleaf Medical AB

Greenleaf Medical is a Swedish research and development company, active in the global nutraceutical market, which sells and develops natural ingredients with well-documented, beneficial health effects. Greenleaf Medical works together with universities and international science and regulatory groups. Their products are used in both Functional Food and Dietary Supplements.

Greenleaf Medical believes the secret of health and beauty is based on finding the best ingredients through scientific validation. Dedicated to creating natural products with published mechanism-of-action and efficacy studies, the Greenleaf Medical team believes in the unique composition of natural, active ingredients and innovative formula of their supplements.